Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.48 |
| ▸ | NPY1R | P25929 | 7/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24473314 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473521 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473470 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473382 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473300 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473479 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473513 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473464 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473421 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 | |
| SCHEMBL24473383 | 0.90 | NPY4R (0.56) | NPY4RNPY1RNPY2RNTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | NPY4R 62/4885NPY1R 41/4885NPY2R 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.